DNMT1 and myelodysplastic syndrome: The DNMT-inhibitors 5-azacitidine (5-AC) and 5-aza-2’-deoxycytidine (DAC) are FDA-approved for the treatment of hematological malignancies and myelodysplastic syndrome.